ORIC Pharmaceuticals Advances Rinzimetostat into Phase 3 Trial with Strong Early Data
Event summary
- ORIC selected rinzimetostat 400 mg once daily as the Recommended Phase 3 Dose (RP3D) for the Himalayas-1 Phase 3 global trial in post-abiraterone mCRPC, expected to initiate in 1H 2026.
- Rinzimetostat demonstrated compelling safety and efficacy in post-abiraterone mCRPC, with landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively.
- ORIC reported early rinzimetostat data in post-AR inhibitor mCRPC, showing promising durability and reinforcing its potential to restore and sustain the benefit derived from AR inhibitors.
- The company anticipates several enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial.
- ORIC has approximately $420 million in cash and investments, expected to provide runway into 2H 2028 and beyond the anticipated primary endpoint readout from the first Phase 3 trial for rinzimetostat.
The big picture
ORIC Pharmaceuticals is positioning itself as a multi-asset, late-stage oncology company with the advancement of rinzimetostat into a Phase 3 trial. The strong early data for rinzimetostat in post-abiraterone mCRPC suggests a potential best-in-disease profile, which could differentiate it from competitors. The company's robust cash position provides a significant runway, but the success of its clinical trials will be crucial in attracting further investment and achieving regulatory approvals.
What we're watching
- Clinical Trial Progress
- The initiation of the Himalayas-1 Phase 3 trial in 1H 2026 will be critical to watch, as it represents ORIC's first registrational trial for rinzimetostat.
- Data Readouts
- The anticipated program update for rinzimetostat and several enozertinib clinical updates in 2H 2026 will provide key insights into the efficacy and safety of these treatments.
- Financial Runway
- The pace at which ORIC spends its $420 million in cash and investments will determine how long the company can sustain its operations before needing additional funding.
Related topics